Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Sales and Divestitures (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Gains from Sales and Divestitures for 10 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 44.87% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 44.87% increase, with the full-year FY2025 number at $2.1 million, up 44.87% from a year prior.
  • Gains from Sales and Divestitures was $2.1 million for Q4 2025 at Intellia Therapeutics, up from $1.8 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.1 million in Q4 2025 to a low of $26235.0 in Q2 2021.
  • A 5-year average of $777124.6 and a median of $597610.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: rose 23.35% in 2022, then skyrocketed 550.69% in 2023.
  • Intellia Therapeutics' Gains from Sales and Divestitures stood at $119715.0 in 2021, then increased by 23.35% to $147674.0 in 2022, then skyrocketed by 358.48% to $677055.0 in 2023, then soared by 111.75% to $1.4 million in 2024, then surged by 44.87% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Gains from Sales and Divestitures are $2.1 million (Q4 2025), $1.8 million (Q3 2025), and $1.7 million (Q2 2025).